
- BioPharm International's BP Elements, March 2022
- Volume 1
- Issue 3
FDA to Hold Public Symposium on Multi-Identification Biomarkers
FDA will hold a symposium discussing the identification of concepts and terminology for multi-component biomarkers from March 23–24, 2022.
FDA’s Center for Drug Evaluation and Research announced a new virtual workshop slated to happen on March 23–24, 2022. The public meeting, “Identification of Concepts and Terminology for Multi-Component Biomarkers,” will be held to discuss high-level terminology surrounding biomarkers.
According to an FDA press release, the goal of the symposium is to develop multi-component biomarker concepts and terminology, identify areas of conceptual language development, and discuss gaps in terminology for concepts and approaches as it relates to multi-component biomarkers.
The symposium will be held via live webcast for the public from 1:00–3:00 pm ET on both days. A full breakdown of the events schedule can be found
Source:
Articles in this issue
over 3 years ago
The Next Step For COVID-19 Vaccinesover 3 years ago
New England Biolabs Releases Lyophilized Master Mixover 3 years ago
Element Biosciences Partners with Genoox on Validation Projectover 3 years ago
European Patent Office Grants Further Patent to Salipro BiotechNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.